A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.

Amirthalingam P

Current drug safety1 Jan 2026Cited by 2 (Europe PMC)

PMID40337971DOI10.2174/0115748863367086250420011411PepBankPUB-40337971

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studySafety outcome
In VigiAccess, tirzepatide had the most incorrect-dose reports, with 9993 reports (23.82%).
In plain wordsTirzepatide had the most incorrect-dose reports in VigiAccess, with 9993 reports.
Peptide
Tirzepatide
Outcome
Not applicableTirzepatide incorrect-dose reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Tirzepatide incorrect-dose reports
9993 reports
tirzepatide, VigiAccess
Share of reports
23.82%
tirzepatide incorrect dose, as written in the abstract
Source sentences
Summary
Among the patient-related DRPs, the administered incorrect dose (17797; 48.37%) was predominant, and most of the reports were documented for tirzepatide (9993; 23.82%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
Report a problemFND-4033797113
02HumanObservational studySafety outcome
In VigiAccess, tirzepatide had the most off-label use reports, with 4945 reports (17.59%).
In plain wordsTirzepatide had the most off-label use reports in VigiAccess, with 4945 reports.
Peptide
Tirzepatide
Outcome
Not applicableTirzepatide off-label use reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Tirzepatide off-label use reports
4945 reports
tirzepatide, VigiAccess
Share of reports
17.59%
tirzepatide off-label use, as written in the abstract
Source sentences
Summary
Off-label use (13600; 48.37%) was a predominant healthcare practicerelated DRP, most of which were from Tirzepatide (4945; 17.59%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
Report a problemFND-4033797118

Studies that did not test the peptide alone16

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In VigiAccess, pooled GLP-1 receptor agonists had 315952 potential side-effect reports in the selected category.
In plain wordsPooled GLP-1 drugs had 315952 potential side-effect reports in the selected VigiAccess category.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePotential side-effect reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Potential side-effect reports
315,952 reports
All GLP-1 receptor agonists in VigiAccess, injury, poisoning and procedural complications
Source sentences
Summary
Overall, 315952 potential side effects (PSEs) were reported regarding GLP-1 RAs in VigiAccess under injury, poisoning, and procedural complications.
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4033797101
04HumanNot a test of Liraglutide aloneObservational studySafety outcome
In VigiAccess, pooled GLP-1 receptor agonists had 315952 potential side-effect reports in the selected category.
In plain wordsPooled GLP-1 drugs had 315952 potential side-effect reports in the selected VigiAccess category.
Peptide
Liraglutide
Outcome
Not applicablePotential side-effect reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Potential side-effect reports
315,952 reports
All GLP-1 receptor agonists in VigiAccess, injury, poisoning and procedural complications
Source sentences
Summary
Overall, 315952 potential side effects (PSEs) were reported regarding GLP-1 RAs in VigiAccess under injury, poisoning, and procedural complications.
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4033797102
05HumanNot a test of Semaglutide aloneObservational studySafety outcome
In VigiAccess, pooled GLP-1 receptor agonists had 315952 potential side-effect reports in the selected category.
In plain wordsPooled GLP-1 drugs had 315952 potential side-effect reports in the selected VigiAccess category.
Peptide
Semaglutide
Outcome
Not applicablePotential side-effect reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Potential side-effect reports
315,952 reports
GLP-1 receptor agonists, VigiAccess injury, poisoning and procedural complications
Source sentences
Summary
Overall, 315952 potential side effects (PSEs) were reported regarding GLP-1 RAs in VigiAccess under injury, poisoning, and procedural complications.
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4033797103
06HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In VigiAccess, pooled GLP-1 receptor agonists had 315952 potential side-effect reports in the selected category.
In plain wordsPooled GLP-1 drugs had 315952 potential side-effect reports in the selected VigiAccess category.
Peptide
Tirzepatide
Outcome
Not applicablePotential side-effect reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Potential side-effect reports
315,952 reports
GLP-1 receptor agonists, VigiAccess injury, poisoning and procedural complications
Source sentences
Summary
Overall, 315952 potential side effects (PSEs) were reported regarding GLP-1 RAs in VigiAccess under injury, poisoning, and procedural complications.
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4033797104
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In VigiAccess, pooled GLP-1 receptor agonists had 84187 drug-related problem reports.
In plain wordsPooled GLP-1 drugs had 84187 drug-related problem reports in VigiAccess.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDrug-related problem reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Drug-related problem reports
84,187 reports
GLP-1 receptor agonists, VigiAccess
Source sentences
Summary
Out of 315952 PSE reports, 84187 were DRPs of GLP-1 RAs.
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4033797105
08HumanNot a test of Liraglutide aloneObservational studySafety outcome
In VigiAccess, pooled GLP-1 receptor agonists had 84187 drug-related problem reports.
In plain wordsPooled GLP-1 drugs had 84187 drug-related problem reports in VigiAccess.
Peptide
Liraglutide
Outcome
Not applicableDrug-related problem reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Drug-related problem reports
84,187 reports
GLP-1 receptor agonists, VigiAccess
Source sentences
Summary
Out of 315952 PSE reports, 84187 were DRPs of GLP-1 RAs.
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4033797106
09HumanNot a test of Semaglutide aloneObservational studySafety outcome
In VigiAccess, pooled GLP-1 receptor agonists had 84187 drug-related problem reports.
In plain wordsPooled GLP-1 drugs had 84187 drug-related problem reports in VigiAccess.
Peptide
Semaglutide
Outcome
Not applicableDrug-related problem reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Drug-related problem reports
84,187 reports
GLP-1 receptor agonists, VigiAccess
Source sentences
Summary
Out of 315952 PSE reports, 84187 were DRPs of GLP-1 RAs.
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4033797107
10HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In VigiAccess, pooled GLP-1 receptor agonists had 84187 drug-related problem reports.
In plain wordsPooled GLP-1 drugs had 84187 drug-related problem reports in VigiAccess.
Peptide
Tirzepatide
Outcome
Not applicableDrug-related problem reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Drug-related problem reports
84,187 reports
GLP-1 receptor agonists, VigiAccess
Source sentences
Summary
Out of 315952 PSE reports, 84187 were DRPs of GLP-1 RAs.
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4033797108
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In VigiAccess, incorrect dosing predominated among patient-related problems for pooled GLP-1 drugs, with 17797 reports (48.37%).
In plain wordsPooled GLP-1 drugs had 17797 incorrect-dose reports, the predominant patient-related problem.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableIncorrect-dose reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Incorrect-dose reports
17,797 reports
patient-related drug-related problems, GLP-1 receptor agonists
Share of patient-related drug-related problems
48.37%
incorrect dose, as written in the abstract
Source sentences
Summary
Among the patient-related DRPs, the administered incorrect dose (17797; 48.37%) was predominant, and most of the reports were documented for tirzepatide (9993; 23.82%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4033797109
12HumanNot a test of Liraglutide aloneObservational studySafety outcome
In VigiAccess, incorrect dosing predominated among patient-related problems for pooled GLP-1 drugs, with 17797 reports (48.37%).
In plain wordsPooled GLP-1 drugs had 17797 incorrect-dose reports, the predominant patient-related problem.
Peptide
Liraglutide
Outcome
Not applicableIncorrect-dose reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Incorrect-dose reports
17,797 reports
patient-related drug-related problems, GLP-1 receptor agonists
Share of patient-related drug-related problems
48.37%
incorrect dose, as written in the abstract
Source sentences
Summary
Among the patient-related DRPs, the administered incorrect dose (17797; 48.37%) was predominant, and most of the reports were documented for tirzepatide (9993; 23.82%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4033797110
13HumanNot a test of Semaglutide aloneObservational studySafety outcome
In VigiAccess, incorrect dosing predominated among patient-related problems for pooled GLP-1 drugs, with 17797 reports (48.37%).
In plain wordsPooled GLP-1 drugs had 17797 incorrect-dose reports, the predominant patient-related problem.
Peptide
Semaglutide
Outcome
Not applicableIncorrect-dose reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Incorrect-dose reports
17,797 reports
patient-related drug-related problems, GLP-1 receptor agonists
Share of patient-related drug-related problems
48.37%
incorrect dose, as written in the abstract
Source sentences
Summary
Among the patient-related DRPs, the administered incorrect dose (17797; 48.37%) was predominant, and most of the reports were documented for tirzepatide (9993; 23.82%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4033797111
14HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In VigiAccess, incorrect dosing predominated among patient-related problems for pooled GLP-1 drugs, with 17797 reports (48.37%).
In plain wordsPooled GLP-1 drugs had 17797 incorrect-dose reports, the predominant patient-related problem.
Peptide
Tirzepatide
Outcome
Not applicableIncorrect-dose reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Incorrect-dose reports
17,797 reports
patient-related drug-related problems, GLP-1 receptor agonists
Share of patient-related drug-related problems
48.37%
incorrect dose, as written in the abstract
Source sentences
Summary
Among the patient-related DRPs, the administered incorrect dose (17797; 48.37%) was predominant, and most of the reports were documented for tirzepatide (9993; 23.82%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4033797112
15HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In VigiAccess, off-label use predominated among healthcare practice-related problems for pooled GLP-1 drugs, with 13600 reports (48.37%).
In plain wordsPooled GLP-1 drugs had 13600 off-label use reports, the predominant healthcare practice-related problem.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableOff-label use reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Off-label use reports
13,600 reports
healthcare practice-related drug-related problems, GLP-1 receptor agonists
Share of healthcare practice-related drug-related problems
48.37%
off-label use, as written in the abstract
Source sentences
Summary
Off-label use (13600; 48.37%) was a predominant healthcare practicerelated DRP, most of which were from Tirzepatide (4945; 17.59%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4033797114
16HumanNot a test of Liraglutide aloneObservational studySafety outcome
In VigiAccess, off-label use predominated among healthcare practice-related problems for pooled GLP-1 drugs, with 13600 reports (48.37%).
In plain wordsPooled GLP-1 drugs had 13600 off-label use reports, the predominant healthcare practice-related problem.
Peptide
Liraglutide
Outcome
Not applicableOff-label use reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Off-label use reports
13,600 reports
healthcare practice-related drug-related problems, GLP-1 receptor agonists
Share of healthcare practice-related drug-related problems
48.37%
off-label use, as written in the abstract
Source sentences
Summary
Off-label use (13600; 48.37%) was a predominant healthcare practicerelated DRP, most of which were from Tirzepatide (4945; 17.59%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4033797115
17HumanNot a test of Semaglutide aloneObservational studySafety outcome
In VigiAccess, off-label use predominated among healthcare practice-related problems for pooled GLP-1 drugs, with 13600 reports (48.37%).
In plain wordsPooled GLP-1 drugs had 13600 off-label use reports, the predominant healthcare practice-related problem.
Peptide
Semaglutide
Outcome
Not applicableOff-label use reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Off-label use reports
13,600 reports
healthcare practice-related drug-related problems, GLP-1 receptor agonists
Share of healthcare practice-related drug-related problems
48.37%
off-label use, as written in the abstract
Source sentences
Summary
Off-label use (13600; 48.37%) was a predominant healthcare practicerelated DRP, most of which were from Tirzepatide (4945; 17.59%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4033797116
18HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In VigiAccess, off-label use predominated among healthcare practice-related problems for pooled GLP-1 drugs, with 13600 reports (48.37%).
In plain wordsPooled GLP-1 drugs had 13600 off-label use reports, the predominant healthcare practice-related problem.
Peptide
Tirzepatide
Outcome
Not applicableOff-label use reports
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Off-label use reports
13,600 reports
healthcare practice-related drug-related problems, GLP-1 receptor agonists
Share of healthcare practice-related drug-related problems
48.37%
off-label use, as written in the abstract
Source sentences
Summary
Off-label use (13600; 48.37%) was a predominant healthcare practicerelated DRP, most of which were from Tirzepatide (4945; 17.59%).
2 context sentences(design, population, supporting numbers)
Summary · context
The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess.
Summary · context
The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice- related.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4033797117

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 6Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 5
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 4
21 Oct 2026, 18:59 UTC
The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.